Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 10;62(4):581-592.
doi: 10.1515/cclm-2023-0609. Print 2024 Mar 25.

Cardiovascular risk evaluation in pregnancy: focus on cardiac specific biomarkers

Clerico Aldo  1 , Zaninotto Martina  2 , Aimo Alberto  3 , Plebani Mario  4 ; Study Group on Cardiac Biomarkers of the Italian Societies of Laboratory Medicine
Affiliations
Review

Cardiovascular risk evaluation in pregnancy: focus on cardiac specific biomarkers

Clerico Aldo et al. Clin Chem Lab Med. .

Abstract

Despite the evidence demonstrating the clinical utility of cardiac specific biomarkers in improving cardiovascular risk evaluation in several clinical conditions, even the most recent reviews and guidelines fail to consider their measurement in order to enhance the accuracy of the evaluation of cardiovascular risk in pregnant women. The aim of this review article was to examine whether the assay of cardiac specific biomarkers can enhance cardiovascular risk evaluation in pregnant women, first by reviewing the relationships between the physiological state of pregnancy and cardiac specific biomarkers. The clinical relevance of brain natriuretic peptide (BNP)/NT-proBNP and high-sensitivity cardiac troponin I/high-sensitivity cardiac troponin T (hs-cTnI/hs-cTnT) assay in improving cardiovascular risk evaluation is examined based on the results of clinical studies on subjects with normal and those with complicated pregnancy. Finally, the analytical approaches and clinical objectives related to cardio specific biomarkers are advocated in order to allow an early and more accurate evaluation of cardiovascular risk in pregnant women.

Keywords: biological variation; cardiac troponins; cardiovascular risk; myocardial injury; natriuretic peptides; pregnancy.

PubMed Disclaimer

References

    1. Knight, M. The findings of the MBRRACE-UK confidential enquiry into maternal deaths and morbidity. Obstet Gynaecol Reprod Med 2019;29:21–3. https://doi.org/10.1016/j.ogrm.2018.12.003 . - DOI
    1. Kotit, S, Yacoub, M. Cardiovascular adverse events in pregnancy: a global perspective. Glob Cardiol Sci Pract 2021;5:e202105. https://doi.org/10.21542/gcsp.2021.5 . - DOI
    1. Hameed, AB, Haddock, A, Wolfe, DS, Florio, K, Drummond, N, Allen, C, et al.. Alliance for innovation on maternal health: consensus bundle on cardiac conditions in obstetric care. Obstet Gynecol 2023;141:253–63. https://doi.org/10.1097/aog.0000000000005048 . - DOI
    1. Markovitz, AR, Stuart, JJ, Horn, J, Williams, PL, Rimm, EB, Missmer, SA, et al.. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway. Eur Heart J 2019;40:113–20. https://doi.org/10.1093/eurheartj/ehy863 . - DOI
    1. Grandi, SM, Filion, KB, Yoon, S, Ayele, HT, Doyle, CM, Hutcheon, JA, et al.. Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications. Circulation 2019;139:1069–79. https://doi.org/10.1161/circulationaha.118.036748 . - DOI

LinkOut - more resources